FDA Ready To Change Bioequivalence Standards, Pending Advisory Committee Input
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency appears ready to narrow bioequivalence standards across the board for generic drug approvals and set up specific requirements for certain drugs with complicated dosing, but is looking to the Pharmaceutical Science advisory panel for final advice on whether the moves are necessary.